FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
FTC releases second report on PBM price hikes of specialty drugs
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from 2017 to 2022.
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
FTC: Three major PBMs inflated drug prices by $7.3 billion from 2017-2022
CNBC's Bertha Coombs reports on the latest news from the FTC.
Pharma digs in on changes it wants from Trump administration
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
STAT1d
Will PBM reform save pharmacies from closing?
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
FTC Launches Inquiry of Single-Family Rental Home 'Mega Investors,' Issues PBM Report
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
pharmaphorum1d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Fierce Healthcare2d
Industry Voices—Why the great unraveling of PBMs will accelerate in 2025
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The PBM Bill Failed: Implications For PBM Reform
The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
Will Congress get another shot at PBM reform?
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Congress missed a chance at PBM reforms.
penncapital-star7h
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...